Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD (NCT04500847)
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Medical Center — Los Angeles, California
Age range: 50 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Cedars-Sinai Medical Center — Los Angeles, California
- Memory and Aging Program, Butler Hospital — Providence, Rhode Island
📞 Contact the Study Coordinator
Phone: (401) 455-6403
Email: MRiddle@butler.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer Disease, Early Onset
- Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study — Winston-Salem, North Carolina
- Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease — Baltimore, Maryland
- Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease — Chandler, Arizona
- PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) — Irvine, California
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau — New York, New York
Explore by condition: All Alzheimer Disease, Early Onset clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.